Position in ADCT
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$2,592,281
+$494,558 QoQ
Shares Held
691,275
+16.3% QoQ
Ownership
0.543%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 67%
Shared 0%
None 33%
Common Shares in ADCT Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026PANAGORA ASSET MANAGEMENT INC holds $89,743,991 across 13 Drug Manufacturers - Specialty & Generic names. ADCT ranks #6 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALKS |
Alkermes plc.
|
932,942 | $32,988,829 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
34,953 | $20,726,429 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
151,449 | $19,951,891 | |
| 4 | ELAN |
Elanco Animal Health Inc
|
260,686 | $6,238,215 | |
| 5 | HROW |
Harrow, Inc.
|
86,097 | $3,035,780 | |
| 6 | ADCT |
ADC Therapeutics SA
This page
|
691,275 | $2,592,281 | |
| 7 | ZTS |
Zoetis Inc.
|
15,203 | $1,797,146 | |
| 8 | BCRX |
Biocryst Pharmaceuticals Inc
|
88,876 | $846,099 |
All Filings in ADCT
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,592,281 | 691,275 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $2,097,723 | 594,256 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $2,177,044 | 544,261 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $727,242 | 271,359 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $76,402 | 54,186 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||